Leveraging a unique AI-driven discovery platformto unleash the therapeutic potential of mTOR inhibition
We are committed to translating cutting-edge mTOR research
into transformative therapies that can significantly impact patient lives.
Aukera Therapeutics is a preclinical-stage biotech spin-off from the University of Basel, emerged from pioneering research on mTOR biology
We develop first-in-class fully selective mTORC1 inhibitors, addressing rare neurological disorders and cancer
We leverage our AI-supported protein design platform to enable discovery on hard-to-drug and complex targets
Team
Stefan Imseng
Chief Executive Officer
Andreas Mühlemann
Head of Biology
Jutta Heim
Chair of the Board
Okke Melse
Computational & Medicinal Chemistry
Matthias Wälchli
Protein Sciences & Structural Biology
Werner Neidhart
Medicinal Chemistry Advisor
We love to hear from you!
© Copyright Aukera Therapeutics. All Rights Reserved.